-
New Perspectives on Fetal and Placental Responses to Diabetes and Its Treatment
Marlena Fejzo, PhD, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 1:30 p.m. CT.
-
Ready for Prime Time?—Pharmacoepidemiology and Real-World Evidence
Sara Jane Cromer, MD, MS, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Friday, June 20, at 3:45 p.m. CT.
-
Heterogeneity of Diabetes—New Initiatives from NIDDK
Michael Bancks, PhD, MPH, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Monday, June 23, at 3:15 p.m. CT.
-
Genetic Regulation of Beta-Cell Mass and Function in Humans—Lessons from GWAS and Rare Genetics
Anna Gloyn, DPhil, and Romina J. Bevacqua, PhD, preview presentations at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 1:30 p.m. CT.
-
Unraveling the Code—Multiomic Insights into Diabetic Foot Ulcer Healing
Kanhaiya Singh, PhD, and Manoj K. Bhasin, PhD, preview presentations at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 8:00 a.m. CT.
-
Health Access Symposium—Community Interventions and Connections
Perina Gaines, BSN, RN, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 4:30 p.m. CT.
-
Show Me the Data! Using Continuous Glucose Monitoring Data to Drive Behavior Change
Sarah Hormachea, MS, RD, CDCES, BC-ADM, and Rachel Stahl Salzman, MS, RD, CDN, CDCES, preview presentations at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 1:30 p.m. CT.
-
Innovative Cellular and Tolerogenic Therapies in Type 1 Diabetes
Paolo Serafini, PhD, previews a presentation at the 85th Scientific Sessions. Attendees in Chicago can watch the session in-person Sunday, June 22, at 1:30 p.m. CT.
-
Researchers to present CV findings from SOUL trial of oral semaglutide in high-risk type 2 diabetes
Investigators, including John B. Buse, MD, PhD, will detail the key findings of a study to determine whether a new oral formulation of semaglutide is a safe and effective alternative to the injectable formulation.
-
Symposium will highlight major STRIDE forward in treating PAD alongside type 2 diabetes
Subodh Verma, MD, PhD, FRCSC, will share key results from a clinical trial using semaglutide in patients with type 2 diabetes and peripheral artery disease.